oral glp-1 agonists Orforglipron, an Small-Molecule Receptor Agonist, in Early Type 2 Diabetes Another milestone in the evolution
Description
10.1002/dmrr.2561 60
10.1038/s41366-024-01473-y [DOI] [PMC free article] [PubMed] [Google Scholar] 74
Safety outcomes included hypoglycaemia, gastrointestinal adverse events, treatment discontinuation due to adverse events, serious adverse events, and mortality
Responsive lobbies and lightweight game clients ensure that the same high-quality graphics and sound are available on smartphones, tablets, and desktops
5 Discussion GLP-1RAs have emerged as a paradigm-shifting class of agents, with therapeutic benefits that extend well beyond glycemic control in type 2 diabetes
Nausea, diarrhea, and vomiting most common
